Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease
This narrative review maps mechanisms by which gut microbiome metabolites influence CVD but generates no primary data and establishes neither causality nor the efficacy of any intervention.
| Population | Adults with or at risk of CVD (atherosclerosis, hypertension, heart failure) |
|---|---|
| Intervention | Gut microbiome modulation via diet, probiotics, prebiotics, postbiotics, TMAO inhibitors, fecal microbiota transplant, or pharmacological interventions targeting microbial metabolites |
| Comparator | No intervention, placebo, or standard care (variable across cited primary studies) |
| Outcome | TMAO-associated cardiovascular risk; Blood pressure and SCFAs; Atherosclerosis progression and microbiome; Gut barrier integrity and butyrate; Systemic inflammation and microbial metabolites; Lipid profile and SCFAs; Major cardiovascular events with microbiome intervention |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| TMAO-associated cardiovascular risk | dose-dependent correlation reported in meta-analyses >26000 individuals; in the pooled RR or 95% CI provided in this review | — | Low | — | |
| Blood pressure and SCFAs | association reported in animal models and limited human observational data; in the pooled effect size or 95% CI provided | — | Low | — | |
| Atherosclerosis progression and microbiome | preclinical data only (ApoE-/- mouse models); in the RCT evidence; in the effect size reported | — | Very low | — | |
| Gut barrier integrity and butyrate | animal model data only; in the quantitative effect size reported | — | Very low | — | |
| Systemic inflammation and microbial metabolites | mechanistic plausibility from preclinical studies; in the RCT-level effect estimate | — | Very low | — | |
| Lipid profile and SCFAs | mixed direction: high-fiber/protein diet increased LDL and BP and decreased HDL in some studies; in the pooled estimate or 95% CI | — | Low | — | |
| Major cardiovascular events with microbiome intervention | no RCT data; not measured in this review | — | Very low | — |
Context
CVD causes 17.9 million deaths per year (WHO, 2019); gut dysbiosis is emerging as an additional risk factor through metabolites such as TMAO, SCFAs, bile acids, and others. The field lacks long-duration RCTs in humans that translate mechanistic findings into measurable clinical benefit.
What the study showed
The review compiles observational and preclinical evidence that elevated TMAO correlates with higher cardiovascular risk in meta-analyses covering >26,000 individuals, without providing effect estimates with 95% CI in the accessed text. SCFAs associate with lower blood pressure and reduced atherosclerosis in animal models, with heterogeneous effects in humans. Secondary bile acids, succinate, imidazole propionate, and tryptophan are described as modulators of inflammation and lipid metabolism, predominantly in preclinical models. No RCT is presented as a primary result of this review.
How it was done
Non-systematic narrative review published in 2025 in Frontiers in Cardiovascular Medicine. No search strategy, inclusion/exclusion criteria, risk-of-bias assessment of primary studies, or pre-registered protocol is specified. Synthesizes literature on microbiome-CVD mechanisms and emerging therapeutic targets.
Effect magnitude
No pooled effect size is reported by the review. Cited primary studies point to a dose-dependent correlation between TMAO and cardiovascular risk, but 95% CIs and RR/OR estimates are not provided in the available full text.
Risk of bias
Narrative review without systematic methodology: no PRISMA protocol, no formal risk-of-bias assessment (RoB 2, ROBINS-I, or AMSTAR-2 not applied). Heterogeneity of cited primary studies (preclinical, observational, small RCTs) precludes causal conclusions. Funding and conflicts of interest are not declared in the available excerpt.
What this study does NOT prove
This review does not prove that any microbiome-targeted intervention reduces cardiovascular events in humans. It does not establish causality between dysbiosis and CVD, nor does it generalize to populations beyond the cited primary studies.
In clinical practice
Clinicians may advise high-fiber, low-excess-choline/carnitine diets as a microbiome-modulation strategy with biological plausibility. Evidence is insufficient to recommend specific SCFA supplementation, probiotics, or TMAO inhibitors outside investigational settings. Monitoring plasma TMAO may assist risk stratification in established CVD patients, but validated clinical protocols do not yet exist.
Limitations
Narrative review without systematic methodology: no PRISMA protocol, no formal risk-of-bias assessment (RoB 2, ROBINS-I, or AMSTAR-2 not applied). Heterogeneity of cited primary studies (preclinical, observational, small RCTs) precludes causal conclusions. Funding and conflicts of interest are not declared in the available excerpt.
What is still missing
Long-duration multicenter RCTs evaluating specific microbiome interventions (e.g., TMA-lyase inhibitors, fecal microbiota transplant) with hard cardiovascular endpoints (MI, stroke, mortality). Dose-response studies for individual SCFAs in populations with established CVD.
Technical appendix
Version history
- 1.0 · 2026-06-21 — Auto-generated under Evidence Standard v1.0